adderall 7.5 Drug Patent Profile
✉ Email this page to a colleague
When do Adderall 7.5 patents expire, and what generic alternatives are available?
Adderall 7.5 is a drug marketed by Teva Womens and is included in one NDA.
The generic ingredient in ADDERALL 7.5 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for adderall 7.5?
- What are the global sales for adderall 7.5?
- What is Average Wholesale Price for adderall 7.5?
Summary for adderall 7.5
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 40 |
Patent Applications: | 1 |
DailyMed Link: | adderall 7.5 at DailyMed |
![adderall 7.5 drug patent expirations Drug patent expirations by year for adderall 7.5](/p/graph/s/t/adderall_7.5-patent-expirations.png)
Recent Clinical Trials for adderall 7.5
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boston Children's Hospital | Phase 1 |
The Beckwith Institute | Phase 4 |
Eva Szigethy | Phase 4 |
Paragraph IV (Patent) Challenges for ADDERALL 7.5
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ADDERALL 7.5 | Tablets | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | 5 mg, 10 mg, 20 mg, 30 mg | 011522 | 1 | 2009-11-18 |
US Patents and Regulatory Information for adderall 7.5
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Womens | ADDERALL 7.5 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | TABLET;ORAL | 011522-011 | Aug 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for adderall 7.5
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Womens | ADDERALL 7.5 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | TABLET;ORAL | 011522-011 | Aug 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for adderall 7.5
See the table below for patents covering adderall 7.5 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 0105407 | ⤷ Sign Up | |
Mexico | PA02000290 | FORMA DE DOSIFICACION ORAL DE LIBERACION INMEDIATA RAPIDA. (RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM.) | ⤷ Sign Up |
Australia | 6089200 | ⤷ Sign Up | |
European Patent Office | 1202739 | ⤷ Sign Up | |
Japan | 2003504406 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |